Evidence map›Paper›PMID 26458958›Full record

ArticleProstate cancer and prostatic diseases2016

Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.

A J Armstrong, P Healy, S Halabi, R Vollmer, A Lark, G Kemeny, K Ware, S J Freedland

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A J ArmstrongDepartment of Medicine/Division of Medical Oncology, Durham, NC, USA.
P HealyDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
S HalabiDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
R VollmerDepartment of Pathology, Duke University and the Durham VA Medical Center, Durham, NC, USA.
A LarkDepartment of Pathology, Duke University and the Durham VA Medical Center, Durham, NC, USA.
G KemenyDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
K WareDepartment of Molecular Genetics and Microbiology, Durham, NC, USA.
S J FreedlandDepartment of Surgery/Division of Urology, Duke University and the Durham VA Medical Center, now at Cedars-Sinai Medical Center, Durham, NC, USA.

Funding

Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS 1K24CA160653NCI NIH HHS K24 CA160653
6 · The paper itself

Abstract

backgroundGiven the potential importance of epithelial plasticity (EP) to cancer metastasis, we sought to investigate biomarkers related to EP in men with localized prostate cancer (PC) for the association with time to PSA recurrence and other clinical outcomes after surgery.

methodsMen with localized PC treated with radical prostatectomy at the Durham VA Medical Center and whose prostatectomy tissues were included in a tissue microarray (TMA) linked to long-term outcomes. We performed immunohistochemical studies using validated antibodies against E-cadherin and Ki-67 and mesenchymal biomarkers including N-cadherin, vimentin, SNAIL, ZEB1 and TWIST. Association studies were conducted for each biomarker with baseline clinical/pathologic characteristics an risk of PSA recurrence over time.

resultsTwo hundred and five men contributed TMA tissue and had long-term follow-up (median 11 years). Forty-three percent had PSA recurrence; three died of PC. The majority had high E-cadherin expression (86%); 14% had low/absent E-cadherin expression. N-cadherin was rarely expressed (<4%) and we were unable to identify an E-to-N-cadherin switch as independently prognostic. No associations with clinical risk group, PSA recurrence or Gleason sum were noted for SNAIL, ZEB1, vimentin or TWIST, despite heterogeneous expression between patients. We observed an association of higher Ki-67 expression with Gleason sum (P=0.043), National Comprehensive Cancer Network risk (P=0.013) and PSA recurrence (hazard ratio 1.07, P=0.016).

conclusionsThe expression of EP biomarkers in this cohort of men with a low risk of PC-specific mortality was not associated with aggressive features or PSA relapse after surgery.

Indexed as

AgedBiomarkers, TumorCadherinsCell PlasticityDisease-Free SurvivalEpithelial CellsHomeodomain ProteinsHumansKi-67 AntigenMaleMiddle AgedNeoplasm Recurrence, LocalNuclear ProteinsProstate-Specific AntigenProstatic NeoplasmsSnail Family Transcription FactorsBiomarkers, TumorCadherinsHomeodomain ProteinsKi-67 AntigenNuclear ProteinsProstate-Specific AntigenSnail Family Transcription FactorsTranscription FactorsTWIST1 protein, humanTwist-Related Protein 1VimentinZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID26458958
PMCPMC4747832

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.